Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: Results from the International Migraine Pain Assessment Clinical Trial (IMPACT)

• Published in: Cephalalgia Vol. 30; no. 11; pp. 1336 - 1345
• Main Authors: Lipton, Richard B, Grosberg, Brian, Singer, Richard P, Pearlman, Starr H, Sorrentino, James V, Quiring, John N, Saper, Joel R
• Format: Journal Article
• Language: English
• Published: UK SAGE Publications 01.11.2010
• Subjects: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Diclofenac - administration & dosage; Diclofenac - adverse effects; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders - drug therapy; Powders; Treatment Outcome; Young Adult; buffered formulation; diclofenac potassium; migraine; acute treatment

Objective: This study assessed the efficacy of diclofenac potassium for oral solution, a novel water-soluble buffered powder formulation, versus placebo for the acute treatment of migraine. Diclofenac potassium for oral solution has a time to maximum plasma concentration (Tmax) of 15 minutes, sugges...